RU2010151944A - Ниацин и нспвс для комбинированной терапии - Google Patents
Ниацин и нспвс для комбинированной терапии Download PDFInfo
- Publication number
- RU2010151944A RU2010151944A RU2010151944/15A RU2010151944A RU2010151944A RU 2010151944 A RU2010151944 A RU 2010151944A RU 2010151944/15 A RU2010151944/15 A RU 2010151944/15A RU 2010151944 A RU2010151944 A RU 2010151944A RU 2010151944 A RU2010151944 A RU 2010151944A
- Authority
- RU
- Russia
- Prior art keywords
- aspirin
- pharmaceutical composition
- hours
- composition according
- period
- Prior art date
Links
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 title claims abstract 80
- 229960003512 nicotinic acid Drugs 0.000 title claims abstract 64
- 235000001968 nicotinic acid Nutrition 0.000 title claims abstract 64
- 239000011664 nicotinic acid Substances 0.000 title claims abstract 64
- 238000002648 combination therapy Methods 0.000 title 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 title 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 title 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims abstract 123
- 229960001138 acetylsalicylic acid Drugs 0.000 claims abstract 123
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 90
- 239000000203 mixture Substances 0.000 claims abstract 30
- 239000003937 drug carrier Substances 0.000 claims abstract 3
- 238000000034 method Methods 0.000 claims 35
- 230000037406 food intake Effects 0.000 claims 11
- 239000011859 microparticle Substances 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 230000036470 plasma concentration Effects 0.000 claims 8
- 206010020565 Hyperaemia Diseases 0.000 claims 7
- 239000003524 antilipemic agent Substances 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 7
- 238000011282 treatment Methods 0.000 claims 7
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 6
- 238000011269 treatment regimen Methods 0.000 claims 5
- 238000013268 sustained release Methods 0.000 claims 4
- 239000012730 sustained-release form Substances 0.000 claims 4
- 210000000941 bile Anatomy 0.000 claims 3
- 239000002775 capsule Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 206010015150 Erythema Diseases 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 2
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 229960005370 atorvastatin Drugs 0.000 claims 2
- 239000003613 bile acid Substances 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 230000001906 cholesterol absorption Effects 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000008030 elimination Effects 0.000 claims 2
- 238000003379 elimination reaction Methods 0.000 claims 2
- 230000029142 excretion Effects 0.000 claims 2
- 229940125753 fibrate Drugs 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 230000000544 hyperemic effect Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 2
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims 2
- 239000003094 microcapsule Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 208000004611 Abdominal Obesity Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 108010074051 C-Reactive Protein Proteins 0.000 claims 1
- 102100032752 C-reactive protein Human genes 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010065941 Central obesity Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010072268 Drug-induced liver injury Diseases 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 1
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 206010024604 Lipoatrophy Diseases 0.000 claims 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims 1
- 102000004895 Lipoproteins Human genes 0.000 claims 1
- 108090001030 Lipoproteins Proteins 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 206010028851 Necrosis Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 1
- 206010035039 Piloerection Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 235000004443 Ricinus communis Nutrition 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 230000002051 biphasic effect Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 235000012343 cottonseed oil Nutrition 0.000 claims 1
- 239000002385 cottonseed oil Substances 0.000 claims 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 208000018914 glucose metabolism disease Diseases 0.000 claims 1
- 208000018578 heart valve disease Diseases 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 230000007803 itching Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 208000006132 lipodystrophy Diseases 0.000 claims 1
- 230000008604 lipoprotein metabolism Effects 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 235000019198 oils Nutrition 0.000 claims 1
- 208000035824 paresthesia Diseases 0.000 claims 1
- 208000008494 pericarditis Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 229940069328 povidone Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 claims 1
- 230000035807 sensation Effects 0.000 claims 1
- 208000013223 septicemia Diseases 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000004448 titration Methods 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5479508P | 2008-05-20 | 2008-05-20 | |
| US61/054,795 | 2008-05-20 | ||
| US10233508P | 2008-10-02 | 2008-10-02 | |
| US61/102,335 | 2008-10-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010151944A true RU2010151944A (ru) | 2012-06-27 |
Family
ID=41258481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010151944/15A RU2010151944A (ru) | 2008-05-20 | 2009-05-20 | Ниацин и нспвс для комбинированной терапии |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20100015220A1 (https=) |
| EP (1) | EP2303327A2 (https=) |
| JP (1) | JP2011521915A (https=) |
| KR (1) | KR20110036540A (https=) |
| CN (1) | CN102083466A (https=) |
| AU (1) | AU2009249600A1 (https=) |
| BR (1) | BRPI0912842A8 (https=) |
| CA (1) | CA2724594A1 (https=) |
| IL (1) | IL209436A0 (https=) |
| MX (1) | MX2010012514A (https=) |
| NZ (1) | NZ589469A (https=) |
| RU (1) | RU2010151944A (https=) |
| WO (1) | WO2009142731A2 (https=) |
| ZA (1) | ZA201008278B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8404275B2 (en) | 2007-07-01 | 2013-03-26 | Vitalis Llc | Combination tablet with chewable outer layer |
| US9074122B2 (en) * | 2008-12-31 | 2015-07-07 | Intevep, S.A. | Mitigation of H2S in steam injection technology using amines of natural origin |
| BRPI1009600A2 (https=) | 2009-06-25 | 2016-03-22 | Tetra S A | |
| US8450316B2 (en) * | 2010-06-24 | 2013-05-28 | Trustees Of Tufts College | Niacin mimetics, and methods of use thereof |
| CA2853804C (en) | 2011-10-28 | 2021-06-01 | Vitalis Llc | Anti-flush compositions |
| CN114146081A (zh) * | 2012-02-07 | 2022-03-08 | 比奥根玛公司 | 含有富马酸二甲酯的药物组合物 |
| DK2861229T3 (da) * | 2012-06-15 | 2021-01-18 | Conaris Res Institute Ag | Farmaceutisk sammensætning indeholdende nikotinsyre og/eller niko-tinamid og/eller tryptophan til positiv påvirkning af tarmmikrobiataen |
| WO2015061442A1 (en) * | 2013-10-22 | 2015-04-30 | Cadila Healthcare Limited | Delayed release pharmaceutical compositions of salsalate |
| KR20150050406A (ko) * | 2013-10-29 | 2015-05-08 | 한림대학교 산학협력단 | 니코틴아마이드 라이보사이드를 유효성분으로 포함하는 패혈증 치료 또는 예방용 약제학적 조성물 |
| WO2015148522A1 (en) | 2014-03-24 | 2015-10-01 | Seals Douglas R | Methods for treatment of vascular endothelial dysfunction using nicotinamide mononucleotide |
| WO2016077832A2 (en) | 2014-11-14 | 2016-05-19 | Gemphire Therapeutics Inc. | PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS |
| US9863094B2 (en) | 2015-02-11 | 2018-01-09 | Westrock Mwv, Llc | Printable compostable paperboard |
| HK1257929A1 (zh) * | 2015-11-06 | 2019-11-01 | Gemphire Therapeutics Inc. | 治疗混合性血脂异常 |
| CN106659729A (zh) * | 2015-12-11 | 2017-05-10 | 邦泰生物工程(深圳)有限公司 | 烟酰胺单核苷酸在制备防治动脉硬化、心脑血管疾病的药物中的应用及其药物 |
| WO2016188092A1 (zh) * | 2015-12-11 | 2016-12-01 | 邦泰生物工程(深圳)有限公司 | 烟酰胺单核苷酸在制备防治动脉硬化、心脑血管疾病的保健品中的应用及其保健品 |
| CA3059073A1 (en) | 2017-04-18 | 2018-10-25 | Gemphire Therapeutics Inc. | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor |
| CN110893179A (zh) * | 2019-12-13 | 2020-03-20 | 沈阳东星医药科技有限公司 | 一种阿司匹林缓释胶囊及其制备方法 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) * | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4410545A (en) * | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4328245A (en) * | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4409239A (en) * | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| HU196714B (en) * | 1984-10-04 | 1989-01-30 | Monsanto Co | Process for producing non-aqueous composition comprising somatotropin |
| IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) * | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| US5612059A (en) * | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| US4970081A (en) * | 1989-01-03 | 1990-11-13 | Sterling Drug Inc. | Controlled-release, low-dose aspirin formulation and method of treating vascular occlusive disease therewith |
| IT1229203B (it) * | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) * | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) * | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) * | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| TW333456B (en) * | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5591767A (en) * | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| FR2704146B1 (fr) * | 1993-04-19 | 1995-07-13 | Cripdom | Microcapsules d'acide acétylsalicylique à libération contrôlée. |
| US6087324A (en) * | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| IT1270594B (it) * | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| FR2725623A1 (fr) * | 1994-10-18 | 1996-04-19 | Flamel Tech Sa | Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os |
| AU5787996A (en) * | 1995-04-19 | 1996-11-07 | Lipoprotein Technologies, Inc. | Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs |
| AU6242096A (en) * | 1995-06-27 | 1997-01-30 | Takeda Chemical Industries Ltd. | Method of producing sustained-release preparation |
| US5855915A (en) * | 1995-06-30 | 1999-01-05 | Baylor University | Tablets or biologically acceptable implants for long-term antiinflammatory drug release |
| TW448055B (en) * | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) * | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US5980945A (en) * | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US6264970B1 (en) * | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) * | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| CA2217134A1 (en) * | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| PT839525E (pt) * | 1996-10-31 | 2004-10-29 | Takeda Chemical Industries Ltd | Preparacao de libertacao prolongada |
| WO1998027980A2 (en) * | 1996-12-20 | 1998-07-02 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
| US5891474A (en) * | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| EP1792616B1 (en) * | 1997-07-31 | 2009-12-16 | Abbott Respiratory LLC | Composition comprising an HMG-CoA inhibitor and a nicotinic acid compound for treating hyperlipidemia |
| US6469035B1 (en) * | 1997-07-31 | 2002-10-22 | Eugenio A. Cefali | Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid |
| US6350458B1 (en) * | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
| US6613358B2 (en) * | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| KR19990085365A (ko) * | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| AR041089A1 (es) * | 2003-05-15 | 2005-05-04 | Merck & Co Inc | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
| US20080058292A1 (en) * | 2003-10-29 | 2008-03-06 | Raif Tawakol | Method for increasing HDL and HDL-2b levels |
| WO2005041878A2 (en) * | 2003-10-29 | 2005-05-12 | Tawakol Raif M D | Compositions and methods for increasing hdl and hdl-2b levels |
| US7019022B2 (en) * | 2003-12-15 | 2006-03-28 | Merck Frosst Canada & Co. | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives |
| FR2891459B1 (fr) * | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
| CA2569776A1 (en) * | 2006-02-17 | 2007-08-17 | Kos Life Sciences, Inc. | Low flush niacin formulation |
-
2009
- 2009-05-20 CN CN200980124201XA patent/CN102083466A/zh active Pending
- 2009-05-20 MX MX2010012514A patent/MX2010012514A/es not_active Application Discontinuation
- 2009-05-20 BR BRPI0912842A patent/BRPI0912842A8/pt not_active IP Right Cessation
- 2009-05-20 CA CA2724594A patent/CA2724594A1/en not_active Abandoned
- 2009-05-20 RU RU2010151944/15A patent/RU2010151944A/ru not_active Application Discontinuation
- 2009-05-20 EP EP09750962A patent/EP2303327A2/en not_active Withdrawn
- 2009-05-20 KR KR1020107028450A patent/KR20110036540A/ko not_active Withdrawn
- 2009-05-20 US US12/469,653 patent/US20100015220A1/en not_active Abandoned
- 2009-05-20 JP JP2011510511A patent/JP2011521915A/ja active Pending
- 2009-05-20 NZ NZ589469A patent/NZ589469A/xx not_active IP Right Cessation
- 2009-05-20 WO PCT/US2009/003119 patent/WO2009142731A2/en not_active Ceased
- 2009-05-20 AU AU2009249600A patent/AU2009249600A1/en not_active Abandoned
-
2010
- 2010-11-18 IL IL209436A patent/IL209436A0/en unknown
- 2010-11-18 ZA ZA2010/08278A patent/ZA201008278B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009142731A3 (en) | 2010-01-14 |
| CN102083466A (zh) | 2011-06-01 |
| NZ589469A (en) | 2012-08-31 |
| IL209436A0 (en) | 2011-01-31 |
| WO2009142731A2 (en) | 2009-11-26 |
| EP2303327A2 (en) | 2011-04-06 |
| ZA201008278B (en) | 2013-09-25 |
| KR20110036540A (ko) | 2011-04-07 |
| BRPI0912842A2 (pt) | 2015-10-13 |
| MX2010012514A (es) | 2011-05-30 |
| CA2724594A1 (en) | 2009-11-26 |
| BRPI0912842A8 (pt) | 2019-01-29 |
| JP2011521915A (ja) | 2011-07-28 |
| AU2009249600A1 (en) | 2009-11-26 |
| US20100015220A1 (en) | 2010-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010151944A (ru) | Ниацин и нспвс для комбинированной терапии | |
| JP2011521915A5 (https=) | ||
| CA2653787C (en) | Composition for preventing the occurrence of cardiovascular event in multiple risk patient | |
| JP2020055816A (ja) | 放出が改良された１−［（３−ヒドロキシ−アダマント−１−イルアミノ）−アセチル］−ピロリジン−２（ｓ）−カルボニトリル製剤 | |
| EP3632440A1 (en) | Use of ligustrazine nitrone derivatives in prevention and treatment of diabetic complication diseases | |
| Ishikawa et al. | Effect of pravastatin and atorvastatin on glucose metabolism in nondiabetic patients with hypercholesterolemia | |
| EP2517697A1 (en) | Combination composition useful for treating cardiovascular diseases | |
| EP2241310A2 (en) | Modified release formulations of emoxypine | |
| US20140128402A1 (en) | Pharmaceutical combination | |
| EP2588108A2 (en) | Treatment for dyslipidemia | |
| KR20110117758A (ko) | 베타 아드레날린 차단제 및 ＨＭＧ－ＣｏＡ 환원 효소 억제제를 함유하는 약제학적 제제 | |
| KR20110046555A (ko) | 레보도파, 카비도파 및 엔타카폰 또는 이의 염을 포함하는 단일 단위 경구 투여 약학 조성물 | |
| CN102014896A (zh) | 包含西坦和肉毒碱的药物组合物及其制备方法 | |
| AU2011339150B2 (en) | Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof | |
| KR20050090443A (ko) | 랑게르한스섬 세포 수를 증가시킴으로써 당뇨병을 치료하는키뉴레닌-３-하이드록실라제 저해제 | |
| TW200412974A (en) | Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure | |
| KR100646576B1 (ko) | 고지혈증 환자의 동맥경화증 예방을 위한 에이치엠지이-씨오에이 환원효소 저해제 및 장용코팅된 아스피린을 함유하는 복합 펠렛 | |
| WO2006130901A1 (en) | Control of metabolic abnormalities | |
| AU2019315823A1 (en) | New use of carbamate beta phenylethanolamine analogues for enhancing intracellular clearance of ldl cholesterol and for combining therapy with statins to enhance the efficacy and reduce adverse effects | |
| KR100648825B1 (ko) | 당뇨병 환자의 동맥경화증 예방을 위한 혈당강하제, 에이치엠지이-씨오에이 환원효소 저해제 및 장용코팅된 아스피린을 함유하는 복합 펠렛 | |
| Panina | The DPP‐4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond | |
| WO2008010008A2 (en) | Cardiovascular combinations using rennin-angiotensin inhibitors | |
| BR102013028912A2 (pt) | composição farmacêutica, forma farmacêutica oral, cápsula, comprimido de dupla camada, usos, método de tratamento de hipercolesterolemia, hipertrigliceridemia e/ou dislipidemia mista e método de prevenção de aterosclerose, diabetes ou prevenção secundária de outras doenças cardiovasculares | |
| Ram | Direct renin inhibitors: a new approach to antihypertensive drug treatment | |
| FR3040303A1 (fr) | Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20140217 |